

**Supplementary Table 6: Post-match baseline characteristics by combotherapy group**

Characteristic	Sulfonylurea (n = 4,498)	'Other' (n = 4,498)	SMD
<b>Demographics</b>			
Age (years)	56.7 ± 13.6	56.3 ± 12.6	0.031
Sex (% female)	1,984 (44.1%)	2,010 (44.7%)	0.012
<b>Geographic/Socioeconomic Status</b>			
Rural/Income Quintile 1	282 (6.3%)	275 (6.1%)	0.007
Rural/Income Quintile 2	284 (6.3%)	279 (6.2%)	0.005
Rural/Income Quintile 3	311 (6.9%)	287 (6.4%)	0.021
Rural/Income Quintile 4	298 (6.6%)	313 (7.0%)	0.013
Rural/Income Quintile 5	332 (7.4%)	328 (7.3%)	0.003
Urban/Income Quintile 1	496 (11.0%)	508 (11.3%)	0.008
Urban/Income Quintile 2	620 (13.8%)	625 (13.9%)	0.003
Urban/Income Quintile 3	619 (13.8%)	611 (13.6%)	0.005
Urban/Income Quintile 4	619 (13.8%)	643 (14.3%)	0.015
Urban/Income Quintile 5	608 (13.5%)	606 (13.5%)	0.001
Unknown	29 (0.5%)	23 (0.5%)	0.018
<b>Baseline Comorbidities</b>			
Alcohol abuse	82 (1.8%)	75 (1.7%)	0.012
Amputation	10 (0.2%)	9 (0.2%)	0.005
Asthma	690 (15.3%)	694 (15.4%)	0.002
CKD	100 (2.2%)	107 (2.4%)	0.010
COPD	366 (8.1%)	382 (8.5%)	0.013
Cardiovascular disease	1,090 (24.2%)	1,066 (23.7%)	0.012
Dementia	110 (2.4%)	92 (2.0%)	0.027
Hypertension	3,011 (66.9%)	3,005 (66.8%)	0.003
Hyperlipidemia	1,725 (38.4%)	1,768 (39.3%)	0.013
Liver disease	278 (6.2%)	284 (6.3%)	0.006
Malignancy	494 (11.0%)	453 (10.1%)	0.030
Microvascular disease	986 (21.7%)	996 (22.2%)	0.005
Obesity	350 (7.8%)	364 (8.1%)	0.012
<b>Baseline Medication Use</b>			
ACE inhibitors	1,756 (39.0%)	1,753 (39.0%)	0.001
Anticoagulants	156 (3.5%)	173 (3.8%)	0.020
Anti-platelets	676 (15.0%)	661 (14.7%)	0.009
ARBs	1,121 (23.5%)	1,084 (24.1%)	0.019
Beta blockers	894 (19.9%)	902 (20.1%)	0.004
CCBs	858 (19.1%)	881 (19.6%)	0.013
Digoxin	76 (1.7%)	77 (1.7%)	0.002
Direct Vasodilators	9 (0.2%)	9 (0.2%)	0.000
Loop diuretics	319 (7.1%)	307 (6.8%)	0.010
Potassium sparing diuretics	79 (1.8%)	76 (1.7%)	0.005
Thiazide diuretics	599 (13.3%)	615 (13.7%)	0.010
Statins	2,407 (53.5%)	2,431 (54.0%)	0.011
Other lipid lowering medications	340 (7.6%)	335 (7.4%)	0.004

<b>Index Fiscal Year</b>			
2006/07	581 (12.9%)	584 (13.0%)	0.002
2007/08	395 (8.8%)	375 (8.3%)	0.016
2008/09	259 (5.8%)	263 (5.8%)	0.004
2009/10	312 (6.9%)	295 (6.6%)	0.015
2010/11	227 (5.0%)	247 (5.5%)	0.020
2011/12	245(5.4%)	253 (5.6%)	0.008
2012/13	283 (6.3%)	297 (6.6%)	0.013
2013/14	258 (5.7%)	271 (6.0%)	0.012
2014/15	462 (10.3%)	468 (10.4%)	0.004
2015/16	857 (19.1%)	852 (18.9%)	0.003
2016/17	619 (13.8%)	593 (13.2%)	0.017
<b>Time on metformin before add-on therapy</b>			
≥ 3 years	1,314 (29.2%)	1,339 (29.8%)	0.012
1 - 3 years	1,168 (26.0%)	1,145 (25.5%)	0.012
< 1 year	2,016 (44.8%)	2,014 (44.8%)	<0.001

† ACE - Angiotensin-converting enzyme; ARB - Angiotensin II receptor blocker; CCB - calcium channel blocker; COPD - chronic obstructive pulmonary disease; PVD - peripheral vascular disease; SMD - standardized mean difference.